- About this Journal ·
- Abstracting and Indexing ·
- Advance Access ·
- Aims and Scope ·
- Article Processing Charges ·
- Articles in Press ·
- Author Guidelines ·
- Bibliographic Information ·
- Citations to this Journal ·
- Contact Information ·
- Editorial Board ·
- Editorial Workflow ·
- Free eTOC Alerts ·
- Publication Ethics ·
- Reviewers Acknowledgment ·
- Submit a Manuscript ·
- Subscription Information ·
- Table of Contents
Journal of Ophthalmology
Volume 2013 (2013), Article ID 529187, 4 pages
18-Fluorodeoxyglucose Uptake by Positron Emission Tomography in Extraocular Muscles of Patients with and without Graves' Ophthalmology
1Instituto de Oftalmología “Fundación de Asistencia Privada Conde de Valenciana I.A.P.”, 06800 Mexico City, DF, Mexico
2Unidad PET/CT Ciclotrón, Facultad de Medicina, Universidad Nacional Autónoma de México, 04510 Mexico City, DF, Mexico
Received 17 August 2012; Revised 5 December 2012; Accepted 9 January 2013
Academic Editor: Lawrence S. Morse
Copyright © 2013 Leonardo García-Rojas et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
- J. A. Garrity and R. S. Bahn, “Pathogenesis of graves ophthalmopathy: implications for prediction, prevention, and treatment,” American Journal of Ophthalmology, vol. 142, no. 1, pp. 147–153, 2006.
- R. S. Bahn and A. E. Heufelder, “Pathogenesis of Graves' ophthalmopathy,” New England Journal of Medicine, vol. 329, no. 20, pp. 1468–1475, 1993.
- G. B. Bartley, “The epidemiologic characteristics and clinical course of ophthalmopathy associated with autoimmune thyroid disease in Olmstead County, Minnesota,” Transactions of the American Ophthalmological Society, vol. 92, pp. 477–588, 1994.
- R. S. Bahn, “Graves’ Ophthalmopathy,” New England Journal of Medicine, vol. 362, pp. 726–738, 2010.
- J. Pritchard, R. Han, N. Horst, W. W. Cruikshank, and T. J. Smith, “Immunoglobulin activation of T cell chemoattractant expression in fibroblasts from patients with Graves' disease is mediated through the insulin-like growth factor I receptor pathway,” Journal of Immunology, vol. 170, no. 12, pp. 6348–6354, 2003.
- P. J. Dolman and J. Rootman, “VISA classification for graves orbitopathy,” Ophthalmic Plastic and Reconstructive Surgery, vol. 22, no. 5, pp. 319–324, 2006.
- A. G. Lee, P. W. Brazis, J. A. Garrity, and M. White, “Imaging for neuro-ophthalmic and orbital disease,” American Journal of Ophthalmology, vol. 138, no. 5, pp. 852–862, 2004.
- G. El-Haddad, H. Zhuang, N. Gupta, and A. Alavi, “Evolving role of positron emission tomography in the management of patients with inflammatory and other benign disorders,” Seminars in Nuclear Medicine, vol. 34, no. 4, pp. 313–329, 2004.
- R. D. Finn, “The search for consistency in the manufacture of PET radiopharmaceuticals,” Annals of Nuclear Medicine, vol. 13, no. 6, pp. 379–382, 1999.
- K. R. Zasadny and R. L. Wahl, “Standardized uptake values of normal tissues at PET with 2-[fluorine-18]- fluoro-2-deoxy-D-glucose: Variations with body weight and a method for correction,” Radiology, vol. 189, no. 3, pp. 847–850, 1993.
- S. Osman and H. J. Danpure, “The use of 2-[18F]fluoro-2-deoxy-D-glucose as a potential in vitro agent for labelling human granulocytes for clinical studies by positron emission tomography,” International Journal of Radiation Applications and Instrumentation B, vol. 19, no. 2, pp. 183–190, 1992.
- L. A. Forstrom, B. P. Mullan, J. C. Hung, V. J. Lowe, and L. M. Thorson, “18F-FDG labelling of human leukocytes,” Nuclear Medicine Communications, vol. 21, no. 7, pp. 691–694, 2000.
- T. Ishimori, T. Saga, M. Mamede et al., “Increased 18F-FDG uptake in a model of inflammation: concanavalin A-mediated lymphocyte activation,” Journal of Nuclear Medicine, vol. 43, no. 5, pp. 658–663, 2002.
- P. H. Kuo, T. Monchamp, and P. Deol, “Imaging of inflammation in Graves' ophthalmopathy by positron emission tomography/computed tomography,” Thyroid, vol. 16, no. 4, pp. 419–420, 2006.
- S. C. Burrell and A. D. van den Abbeele, “2-deoxy-2-[F-18]fluoro-D-glucose—positron emission tomography of the head and neck: an atlas of normal uptake and variants,” Molecular Imaging and Biology, vol. 7, no. 3, pp. 244–256, 2005.
- S. Zincirkeser, E. Şahin, M. Halac, and S. Sager, “Standardized uptake values of normal organs on 18F-fluorodeoxyglucose positron emission tomography and computed tomography imaging,” Journal of International Medical Research, vol. 35, no. 2, pp. 231–236, 2007.
- H. Uematsu, N. Sadato, Y. Yonekura et al., “Coregistration of FDG PET and MRI of the head and neck using normal distribution of FDG,” Journal of Nuclear Medicine, vol. 39, no. 12, pp. 2121–2127, 1998.
- S. Nakamura, K. Okochi, Y. Murata, H. Shibuya, and T. Kurabayashi, “[18F]Fluorodeoxyglucose-PET/CT differentiation between physiological and pathological accumulations in head and neck,” Nuclear Medicine Communications, vol. 30, no. 7, pp. 498–503, 2009.
- J. Meller, F. Strutz, U. Siefker et al., “Early diagnosis and follow-up of aortitis with [18F]FDG PET and MRI,” European Journal of Nuclear Medicine and Molecular Imaging, vol. 30, no. 5, pp. 730–736, 2003.